Sinica Inhibitory effects of melatonin on the development of 17-β-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents

Lie Gao, Jian Ping Xu, Hui Min Shan, Rong Zhang, Rong Kun Xu

Research output: Contribution to journalArticle

Abstract

In the present study, we have examined inhibitory effects of melatonin on the development of pituitary prolactin-producing tumors (prolactinoma) induced by 17-β-estradiol (E2) in vivo. The prolactinomas were established by implanting E2-laden silastic capsules subcutaneously in Sprague-Dawley male rats weighing 80-100 g. Melatonin (0.05, 0.25, 0.50, 1.00, and 2.00 mg/0.1 ml/rat) was administrated subcutaneously at 18:00 h for 90 days, beginning from d 7 prior to tumor induction. Controls were given equal volurnes of 4% alcohol in 0.9% saline.Our results showed: (1) In control group and groups given respectively 0.05, 0.25, 0.50, 1.00 and 2.00 mg melatonin, the weight of prolactinoma was 115.0 ± 71.0, 85.2 ± 41.0, 58.9 ± 24.1, 72.7 ± 23.6, 79.3 ± 56.1, 74.5 ± 46.8 mg respectively; the plasma prolactin (PRL) content was 493.46 ± 33.3, 373.78 ± 26.5, 125.13 ± 13.3, 201.79 ± 11.2, 418.88 ± 41.3, 281.94 ± 36.4 ng/ml respectively; the plasma peroxidative lipid content was 1.21 ± 0.23, 0.89 ± 0.32, 0.92 ± 0.27, 0.64 ± 0.24, 0.41 ± 0.14 and 0.43 ± 0.21 △D233/ml respectively. (2) The correlation coefficients between tumor weight and plasma PRL content, tumor weight and plasma peroxydative lipid content, and plasma PRL content and plasma peroxydative lipid content were 0.8738, 0.5550 and 0.2141 respectively. These results indicate: (1) The dosages of 0.25 (P < 0.01) and 0.50 (P < 0.05) mg, but not 0.05 (P > 0.05), 1.00 (P > 0.05) and 2.00 (P > 0.05) mg, melatonin significantly inhibited the development of the E2-induced prolactinoma and the secretion of PRL in comparison with the matched control. (2) The levels of 0.05-2.00 (P < 0.05-0.001) mg melatonin showed a dose-dependent antioxidative action. (3) There are positive correlation between tumor weight and plasma PRL content (P < 0.05), but no correlation between tumor weight and plasma peroxydative lipid content (P > 0.05), and plasma PRL content and plasma peroxidative lipid content (P > 0.05) . Therefore, our experiments demonstrate that the inhibition of the development of E2-induced prolactinoma by adequate dosage of melatonin may be related to the inhibitory effects of MLT on the secretion of PRL, but not to the antioxidative action of MLT.

Original languageEnglish (US)
Pages (from-to)165-169
Number of pages5
JournalActa Physiologica Sinica
Volume53
Issue number3
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

Prolactinoma
Melatonin
Prolactin
Estradiol
Lipids
Tumor Burden
Capsules
Sprague Dawley Rats
Neoplasms
Alcohols
Weights and Measures
Control Groups

Keywords

  • 17-ß-estradiol
  • Antitumorigenesis
  • Melatonin
  • Peroxidative lipid
  • Prolactin
  • Prolactinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sinica Inhibitory effects of melatonin on the development of 17-β-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents. / Gao, Lie; Xu, Jian Ping; Shan, Hui Min; Zhang, Rong; Xu, Rong Kun.

In: Acta Physiologica Sinica, Vol. 53, No. 3, 01.12.2001, p. 165-169.

Research output: Contribution to journalArticle

@article{fd5cb8e6de4c4b0f906e4272e9aa3e06,
title = "Sinica Inhibitory effects of melatonin on the development of 17-β-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents",
abstract = "In the present study, we have examined inhibitory effects of melatonin on the development of pituitary prolactin-producing tumors (prolactinoma) induced by 17-β-estradiol (E2) in vivo. The prolactinomas were established by implanting E2-laden silastic capsules subcutaneously in Sprague-Dawley male rats weighing 80-100 g. Melatonin (0.05, 0.25, 0.50, 1.00, and 2.00 mg/0.1 ml/rat) was administrated subcutaneously at 18:00 h for 90 days, beginning from d 7 prior to tumor induction. Controls were given equal volurnes of 4{\%} alcohol in 0.9{\%} saline.Our results showed: (1) In control group and groups given respectively 0.05, 0.25, 0.50, 1.00 and 2.00 mg melatonin, the weight of prolactinoma was 115.0 ± 71.0, 85.2 ± 41.0, 58.9 ± 24.1, 72.7 ± 23.6, 79.3 ± 56.1, 74.5 ± 46.8 mg respectively; the plasma prolactin (PRL) content was 493.46 ± 33.3, 373.78 ± 26.5, 125.13 ± 13.3, 201.79 ± 11.2, 418.88 ± 41.3, 281.94 ± 36.4 ng/ml respectively; the plasma peroxidative lipid content was 1.21 ± 0.23, 0.89 ± 0.32, 0.92 ± 0.27, 0.64 ± 0.24, 0.41 ± 0.14 and 0.43 ± 0.21 △D233/ml respectively. (2) The correlation coefficients between tumor weight and plasma PRL content, tumor weight and plasma peroxydative lipid content, and plasma PRL content and plasma peroxydative lipid content were 0.8738, 0.5550 and 0.2141 respectively. These results indicate: (1) The dosages of 0.25 (P < 0.01) and 0.50 (P < 0.05) mg, but not 0.05 (P > 0.05), 1.00 (P > 0.05) and 2.00 (P > 0.05) mg, melatonin significantly inhibited the development of the E2-induced prolactinoma and the secretion of PRL in comparison with the matched control. (2) The levels of 0.05-2.00 (P < 0.05-0.001) mg melatonin showed a dose-dependent antioxidative action. (3) There are positive correlation between tumor weight and plasma PRL content (P < 0.05), but no correlation between tumor weight and plasma peroxydative lipid content (P > 0.05), and plasma PRL content and plasma peroxidative lipid content (P > 0.05) . Therefore, our experiments demonstrate that the inhibition of the development of E2-induced prolactinoma by adequate dosage of melatonin may be related to the inhibitory effects of MLT on the secretion of PRL, but not to the antioxidative action of MLT.",
keywords = "17-{\ss}-estradiol, Antitumorigenesis, Melatonin, Peroxidative lipid, Prolactin, Prolactinoma",
author = "Lie Gao and Xu, {Jian Ping} and Shan, {Hui Min} and Rong Zhang and Xu, {Rong Kun}",
year = "2001",
month = "12",
day = "1",
language = "English (US)",
volume = "53",
pages = "165--169",
journal = "Sheng li xue bao : [Acta physiologica Sinica].",
issn = "0371-0874",
publisher = "Kexue Chubaneshe/Science Press",
number = "3",

}

TY - JOUR

T1 - Sinica Inhibitory effects of melatonin on the development of 17-β-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents

AU - Gao, Lie

AU - Xu, Jian Ping

AU - Shan, Hui Min

AU - Zhang, Rong

AU - Xu, Rong Kun

PY - 2001/12/1

Y1 - 2001/12/1

N2 - In the present study, we have examined inhibitory effects of melatonin on the development of pituitary prolactin-producing tumors (prolactinoma) induced by 17-β-estradiol (E2) in vivo. The prolactinomas were established by implanting E2-laden silastic capsules subcutaneously in Sprague-Dawley male rats weighing 80-100 g. Melatonin (0.05, 0.25, 0.50, 1.00, and 2.00 mg/0.1 ml/rat) was administrated subcutaneously at 18:00 h for 90 days, beginning from d 7 prior to tumor induction. Controls were given equal volurnes of 4% alcohol in 0.9% saline.Our results showed: (1) In control group and groups given respectively 0.05, 0.25, 0.50, 1.00 and 2.00 mg melatonin, the weight of prolactinoma was 115.0 ± 71.0, 85.2 ± 41.0, 58.9 ± 24.1, 72.7 ± 23.6, 79.3 ± 56.1, 74.5 ± 46.8 mg respectively; the plasma prolactin (PRL) content was 493.46 ± 33.3, 373.78 ± 26.5, 125.13 ± 13.3, 201.79 ± 11.2, 418.88 ± 41.3, 281.94 ± 36.4 ng/ml respectively; the plasma peroxidative lipid content was 1.21 ± 0.23, 0.89 ± 0.32, 0.92 ± 0.27, 0.64 ± 0.24, 0.41 ± 0.14 and 0.43 ± 0.21 △D233/ml respectively. (2) The correlation coefficients between tumor weight and plasma PRL content, tumor weight and plasma peroxydative lipid content, and plasma PRL content and plasma peroxydative lipid content were 0.8738, 0.5550 and 0.2141 respectively. These results indicate: (1) The dosages of 0.25 (P < 0.01) and 0.50 (P < 0.05) mg, but not 0.05 (P > 0.05), 1.00 (P > 0.05) and 2.00 (P > 0.05) mg, melatonin significantly inhibited the development of the E2-induced prolactinoma and the secretion of PRL in comparison with the matched control. (2) The levels of 0.05-2.00 (P < 0.05-0.001) mg melatonin showed a dose-dependent antioxidative action. (3) There are positive correlation between tumor weight and plasma PRL content (P < 0.05), but no correlation between tumor weight and plasma peroxydative lipid content (P > 0.05), and plasma PRL content and plasma peroxidative lipid content (P > 0.05) . Therefore, our experiments demonstrate that the inhibition of the development of E2-induced prolactinoma by adequate dosage of melatonin may be related to the inhibitory effects of MLT on the secretion of PRL, but not to the antioxidative action of MLT.

AB - In the present study, we have examined inhibitory effects of melatonin on the development of pituitary prolactin-producing tumors (prolactinoma) induced by 17-β-estradiol (E2) in vivo. The prolactinomas were established by implanting E2-laden silastic capsules subcutaneously in Sprague-Dawley male rats weighing 80-100 g. Melatonin (0.05, 0.25, 0.50, 1.00, and 2.00 mg/0.1 ml/rat) was administrated subcutaneously at 18:00 h for 90 days, beginning from d 7 prior to tumor induction. Controls were given equal volurnes of 4% alcohol in 0.9% saline.Our results showed: (1) In control group and groups given respectively 0.05, 0.25, 0.50, 1.00 and 2.00 mg melatonin, the weight of prolactinoma was 115.0 ± 71.0, 85.2 ± 41.0, 58.9 ± 24.1, 72.7 ± 23.6, 79.3 ± 56.1, 74.5 ± 46.8 mg respectively; the plasma prolactin (PRL) content was 493.46 ± 33.3, 373.78 ± 26.5, 125.13 ± 13.3, 201.79 ± 11.2, 418.88 ± 41.3, 281.94 ± 36.4 ng/ml respectively; the plasma peroxidative lipid content was 1.21 ± 0.23, 0.89 ± 0.32, 0.92 ± 0.27, 0.64 ± 0.24, 0.41 ± 0.14 and 0.43 ± 0.21 △D233/ml respectively. (2) The correlation coefficients between tumor weight and plasma PRL content, tumor weight and plasma peroxydative lipid content, and plasma PRL content and plasma peroxydative lipid content were 0.8738, 0.5550 and 0.2141 respectively. These results indicate: (1) The dosages of 0.25 (P < 0.01) and 0.50 (P < 0.05) mg, but not 0.05 (P > 0.05), 1.00 (P > 0.05) and 2.00 (P > 0.05) mg, melatonin significantly inhibited the development of the E2-induced prolactinoma and the secretion of PRL in comparison with the matched control. (2) The levels of 0.05-2.00 (P < 0.05-0.001) mg melatonin showed a dose-dependent antioxidative action. (3) There are positive correlation between tumor weight and plasma PRL content (P < 0.05), but no correlation between tumor weight and plasma peroxydative lipid content (P > 0.05), and plasma PRL content and plasma peroxidative lipid content (P > 0.05) . Therefore, our experiments demonstrate that the inhibition of the development of E2-induced prolactinoma by adequate dosage of melatonin may be related to the inhibitory effects of MLT on the secretion of PRL, but not to the antioxidative action of MLT.

KW - 17-ß-estradiol

KW - Antitumorigenesis

KW - Melatonin

KW - Peroxidative lipid

KW - Prolactin

KW - Prolactinoma

UR - http://www.scopus.com/inward/record.url?scp=0347872615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347872615&partnerID=8YFLogxK

M3 - Article

C2 - 12589398

AN - SCOPUS:0347872615

VL - 53

SP - 165

EP - 169

JO - Sheng li xue bao : [Acta physiologica Sinica].

JF - Sheng li xue bao : [Acta physiologica Sinica].

SN - 0371-0874

IS - 3

ER -